EMA: Response to TB CAB letter

EMA's response to TB CAB letter regarding the filing of the drugs delamanid and bedaquiline for market approval.

/

 

Download the letter from here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By European Medicines Agency

Published: March 22, 2013, 7:24 p.m.

Last updated: March 22, 2013, 8:38 p.m.

Tags: None

Print Share